The EAU Research Foundation is inviting applications to utilise the biological samples (Tissue – FFPE and fresh frozen, Blood – Serum and Urine) that were collected as part of the MAGNOLIA study which has now completed.
The MAGNOLIA study was a randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 CI in patieNts with MAGE-A3 pOsitive muscLe Invasive blAdder cancer after cystectomy. MAGE-A3 CI represents a class of medicines designed to train the immune system in order to recognize as well as eliminate cancer cells in a specific manner. The MAGNOLIA trial was open to male and female patients with histologically confirmed transitional cell carcinoma of bladder urothelium (T2,3 N0 or N1 or N2 and M0 disease or Stage T4 N0 M0 disease after cystectomy) with expression of the MAGE-A3 antigen, and who were free of residual disease and free of metastases.
During the study FFPE block samples of at least 10mm3 of the primary tumour - or in cases where the tissue block was not possible 20-25 unstained 10 µm slides and 1 unstained 5 µm slide of the primary tumour. Fresh tissue of the resected tumour (and in case of recurrence) was also collected. Blood samples (serum) at V1 (pre-adminstration), V3, V5, V7, V8, V10 and concluding visit was collected. Urine Samples prior to cystectomy (and in case of recurrence) have also been collected.
If you have interesting studies that will utilise these samples please contact: Dr. Raymond Schipper for further details of the MAGNOLIA study, access to the sample data base which will inform you of the numbers and types of patients and samples available and an application form.
PO Box 300166803 AA ArnhemThe NetherlandsTel: + 31 26 3890677Fax: +31 26 3890679e-mail: email@example.com